PACB’s revenue has remained relatively stable around $37-$44 million per quarter in recent periods. However, the company consistently incurs large operating and net losses driven by high R&D and SG&A expenses. EBITDA margins are deeply negative, reflecting sustained investment in technology development and business operations.

Revenue growth has been modest and volatile, constrained by the specialized nature of the sequencing market. Gross margin ratios fluctuated around 25-37%, indicating some variability in cost control and pricing power but generally positive gross profitability.

Operating margins remain heavily negative, ranging from about -92% to over -110% in recent quarters. The gross margin improvement has been insufficient to offset the large operating expenses, mainly high R&D costs consistently exceeding $20 million quarterly.

Earnings quality is weak given the ongoing losses, although the company's revenue recognition appears consistent. The substantial volatile other income/expense items have at times cushioned overall net losses but do not reflect core operational profitability.

Year-over-year revenue growth is largely flat to slightly positive, with quarterly revenues around $39 million in the latest periods compared to similar levels one year ago. Growth is insufficiently robust to signal strong top-line momentum.

Earnings remain negative but EPS losses have slightly improved from as low as -$1.44 to about -$0.14 per share most recently, indicating some progress toward narrowing losses over time.

Growth is driven primarily by gradual adoption of the company’s sequencing technology in clinical and research markets, supplemented by ongoing technological enhancements. However, market penetration and sales expansion appear restrained by cost structure and competitive pressures.

Growth remains predominantly organic, supported by ongoing R&D investment. The company has not reported significant acquisitions or inorganic growth, which supports sustainability but also highlights the need for breakthrough innovation or market expansion to accelerate growth.

Gross margins hover between 25% and 37%, showing modest operational profitability at the product level. However, operating margins are deeply negative, typically exceeding -90%, dominated by high R&D and SG&A expenses.

ROE and ROA are deeply negative, matching the substantial net losses and reflecting the company’s lack of profitability. Precise percentages are unavailable but losses exceed 100% of equity and asset bases over recent periods.

Current margin levels are unsustainable long term if losses persist, requiring either significant revenue scale-up or cost reduction to approach breakeven. R&D investments, while vital, limit near-term margin improvement.